Biosimilar Legal Landscape: Lessons From 2017
Executive Summary
In several firsts last year, US Supreme Court ruled on BPCIA, Amgen won a damages award in infringement litigation, and Amgen and Mylan inked deals clearing way for future launch of Humira and Herceptin biosimilars. Chart includes status of 15 cases and questions teed up for courts to tackle in 2018.
You may also be interested in...
Biosimilar Sponsors Are Not Liable Under State Law For Declining Patent Dance
US Federal Circuit finds in Amgen v. Sandoz that the BPCIA preempts innovator companies from seeking penalties under state law against a biosimilar sponsor that does not engage in the 'patent dance.'
Pfizer's Infliximab Biosimilar Approved In US But Won't Launch Against Inflectra
Ixifi (infliximab-qbtx), which references Janssen's Remicade, marks first US approval of a biosimilar developed entirely by Pfizer; big pharma says it is not currently planning to launch Ixifi because it remains "committed" to marketing Celltrion's Inflectra.
Keeping Track: Flurry Of Approvals Rolls Over Into Holiday Season
The latest drug development news and highlights from our US FDA Performance Tracker.